At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

First-line treatment selection in follicular lymphoma is closely tied to tumor stage, disease burden, and patient-specific ...

Follicular lymphoma is often underrecognized not only for its clinical complexity but also for the significant financial ...

The addition of epcoritamab to standard therapy significantly improved PFS for patients with relapsed or refractory follicular lymphoma, according to study results presented at ASH Annual Meeting and ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for ...

While both women and men may experience classic symptoms of lymphoma, women may have different symptoms if the lymphoma has developed in a reproductive organs. Lymphoma is a type of cancer that ...

Fred Hutch researchers pioneered bone marrow transplantation, one of the most significant advances in treating lymphoma, leukemia and other blood cancers. We continue to improve bone marrow and blood ...

Lymphoma is a cancer of the lymphatic system. When lymphoma doesn’t go into remission or recurs quickly, it can sometimes qualify as a disability. People who’ve received bone marrow transplants as ...

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor ...